Background Actinic keratoses (AKs) are epidermal skin lesions with the potential to develop
Introduction
Actinic keratoses (AKs) are premalignant intraepidermal skin lesions, caused by excessive exposure to solar radiation. 1 It is the third most common skin complaint treated by dermatologists in the USA and, according to the American Academy of Dermatology, 60% of predisposed individuals over 40 years of age have at least one lesion. 2, 3 The prevalence of AK is higher in men than in women, increases with age and occurs more frequently in fair-than dark-skinned individuals. 1, 4, 5 Epidemiological and histological features of AKs are similar to those of invasive squamous cell carcinoma (SCC), and the potential for AK to develop into SCC is a serious clinical concern. 3, 4 In a recent study a high incidence of p53 mutations was reported in both AKs and SCC (53% and 69%, respectively). 6 The p53 gene encodes a protein responsible for, amongst others, DNA repair following UV-induced DNA damage. Consequently, AK may be viewed as the initial stage of a continuum beginning with UV-induced DNA damage, leading to neoplastic transformation and proliferation, invasion into deeper structures, and ®nally culminating in metastasis and death. 7 The presence of p53 mutation in AK lesions is consistent with this view. The rate of transformation is estimated between 0.1 and 20%, with a lifetime risk of progression of 6±10%. 8, 9 With currently available treatment modalities, the majority of AKs can be cured (cure rates as high as 90% have been obtained). 10 Liquid nitrogen freezing is the most frequently used method of treatment. 11 However, it is often highly destructive and the freezing method can leave unsightly hypopigmented marks on treated skin. 11 Less common destructive treatments include curettage, electrocautery, dermabrasion, laser and chemical peels, all with similar disadvantages including pigmentation problems. 5, 10 In terms of medical treatment for AK, topical 5-uorouracil (5-FU) is also widely utilized. This method has the advantage of treating large areas and subclinical lesions, but a relatively long treatment period is required and it is only partially effective in removing deep or hyperkeratotic Aks. 10 It also causes unsightly and painful erosions. 12 Therefore, there is a de®nite need for an effective and well-tolerated treatment for AK that is acceptable to patients. An early study of the therapeutic ef®cacy of topical diclofenac in a hyaluronan gel vehicle in patients with AK provided encouraging results and led to the evaluation of this formulation for the treatment of AK. 13 The present study was performed to investigate the therapeutic potential of 3% diclofenac in 2.5% hyaluronan gel in the topical treatment of AK. 
Methods

Study design
Patients
Outpatients aged 18 years or over with a diagnosis of ®ve or more AK lesions were eligible to participate in the study. The lesions had to be contained in one to three 5 cm 2 designated treatment blocks in one or more of the selected Major Body Areas (forehead, central face, scalp, arms, hands). In addition, the lesions were scored according to the investigators' impression of their severity at baseline using the Baseline Severity Index (BSI).
The scale used for determining BSI was as follows: 0 = no AKS visible, 1 = clearly visible lesions, 2 = many visible, small, moderately thick lesions or a few large, thick, rough scaly lesions, 3 = many thick, hypertrophic lesions which are clearly visible and palpable with well de®ned borders.
Patients had to be in good general health, with no other clinically signi®cant medical problems, and women had to be using reliable contraception. Patients were excluded from the study if they had a known allergy to aspirin or other nonsteroidal anti-in¯ammatory drugs (NSAIDs), had a dermatological condition (including psoriasis) in the designated site which might interfere with the absorption, accumulation or metabolism of the study medication, or were being treated with a disallowed concomitant medication (including masoprocol, 5-FU, etretinate, cyclosporine, retinoids, trichloroacetic acid peel or glycolic acid). were chosen as previous studies have shown that the optimal response to treatment is obtained after a slight delay following EOT. 13 
Treatment schedule
Safety assessments
Adverse events
Patients were given a diary to take home, in which to record all applications of study medication, concomitant medications and adverse events. The physician also assessed and recorded adverse events for duration, intensity and causality.
Laboratory analyzes
Standard laboratory analyzes (hematology, biochemistry, urinalysis) were performed on all patients at screening and EOT.
Serology
In order to study the potential sensitization of patients to diclofenac, patients' serum samples obtained at Screening and EOT were assessed for the presence of antidiclofenac antibodies. Serum samples were also obtained at the onset of any clinically signi®cant skin reaction.
Statistical analysis
The sample size calculation was based on the effect on lesion numbers, and determined that 54 patients per group would be suf®cient to detect (with 80% power) an effect size of 0.54. All ef®cacy analyzes were performed on the Intend To Treat (ITT)
cohort. All statistical tests used two-sided P-values rounded to three decimal places. The treatment group differences were assessed using ANOVA.
Results
Patients
A total of 120 patients enrolled for the study, 118 started the treatment and 96 patients completed the study. There were 22 withdrawals from the study. Of these, 14 were from the active treatment group (eight due to adverse events and six due to noncompliance) and eight from the placebo group (four due to adverse events, two due to non compliance and two withdrew consent). The patients were well matched across the treatment groups. Of the comparisons made between the two groups for baseline demographic characteristics, none were statistically signi®cant except for hair color. There was a greater proportion of patients with blonde hair in the active treatment group; however, this was not deemed to present any kind of favorable bias. The distribution and severity (classi®ed according to the BSI) of the lesions across major body areas were also similar in both groups.
There was a high degree of comparability of medical history and concomitant medication between the two groups. Their current medical conditions were also comparable and did not change signi®cantly from baseline to end of treatment. Compliance was deemed excellent.
Ef®cacy (primary outcome measures)
At follow-up, 50% of patients in the active treatment group had TLNS = 0 (indicating complete resolution of all target lesions in a designated area) whereas in the placebo group this value was only 20%, a statistically signi®cant difference (P < 0.001). With regards to CLNS, a signi®cant difference was also observed between the two groups with 47% of patients using active treatment having CLNS = 0 (indicating complete resolution of target and new lesions in a designated area) compared to 19% in the placebo group (P < 0.001) (Fig. 1) .
The Global Improvement Indices followed the trend in the lesion number scores. At follow-up, a signi®cantly greater proportion of patients using active treatment had IGII = 4 (complete lesion improvement) compared to placebo group (47% vs. 19%; P < 0.001). Furthermore, a combined 79% of patients in the active treatment group had achieved complete (IGII = 4) or signi®cant (IGII = 3) lesion improvement compared to 45% in the placebo group. With regards to PGII, 41% in the active treatment group had a score = 4 compared to 17% in the placebo group (P < 0.001). Once again, a combined 77% of patients in the active treatment group had achieved complete (PGII = 4) or signi®cant (PGII = 3) lesion improvement compared to only 33% in the placebo group.
Although not part of the primary outcome measures, it was also noted that no post-treatment hypopigmentation or adverse textural changes in the skin of patients were observed in either group.
Safety and tolerability
Overall, both treatments were well tolerated. At least one adverse event was reported in 90 and 81% of patients in the active treatment and placebo groups, respectively. The majority of adverse events were related to the skin, the most commonly reported (in descending order of frequency) being pruritus, application site reactions, dry skin, rash and erythema. The active treatment was associated with a higher proportion of skin-related adverse events than the placebo group (79% compared with 64%), and in Figure 1 Comparison of the results obtained for the four primary outcome variables for both treatment groups at follow-up (30 days after end of treatment). All comparisons are statistically signi®cant (P < 0.05). For abbreviations refer to text 96% of these cases, the events were classi®ed as mild or moderate. Adverse events reported in the nervous system were all local effects related to application site (paraesthesia, hyperesthesia and tingling) and are unlikely to be clinically signi®cant. In general, there were a comparable number of adverse events categorized as mild or moderate between the active treatment and placebo arms. The majority of adverse events resolved spontaneously and did not require treatment. There were no treatment-related serious adverse events and no deaths in this study. A summary of the adverse events is presented in Table 1 .
Laboratory parameters (hematology, biochemistry, urinalysis) were comparable between groups and no clinically relevant ®ndings were recorded. The serology test results were negative.
Discussion
The use of 3% diclofenac in 2.5% hyaluronan gel was effective and well tolerated for the treatment of AK.
The application of topical diclofenac resulted in a greater rate of lesion resolution in the designated treatment areas.
This was indicated by a greater proportion of patients using diclofenac obtaining TNLS and CLNS = 0 compared to those using hyaluronan alone. The Global Improvement Indices ratings also supported the trends observed in the lesion number scores. The perceived effect however, appears to be slightly lower when rated by patients; this may be due to the fact that even though lesions completely respond to treatment, the skin may still have a slight pink coloration. This can be confused with an incomplete response by the patient.
Overall, diclofenac gel was well tolerated in this study. As expected, the most common adverse events were skinrelated and localized to the designated treatment areas. The majority of these events were assessed as being related to treatment, with a slightly greater number occuring in the active treatment arm. The exception was pruritus, which had a similar incidence in both groups; this may be due to antipruritic effects of diclofenac. 14, 15 Most non skinrelated adverse effects were rated mild or moderate and were not considered to be due to treatment. They were comparable between the two groups and most resolved spontaneously.
The mechanism of action of diclofenac with regards to the treatment of AK is not clearly understood. However, like other NSAIDs, diclofenac has been shown to have antitumorigenic effects, an observation that is currently under investigation. As a NSAID, diclofenac inhibits the cyclooxygenase enzymes (COX-I and COX II), which are involved in arachidonic acid metabolism. It is thought that by inhibiting the metabolism of arachidonic acid, NSAIDs curtail the numerous and potent tumorigenic effects of its metabolites. Such effects include the conversion of procarcinogens to carcinogens, inhibition of immune surveillance, inhibition of apoptosis, stimulation of angiogenesis and increasing the invasiveness of tumor cells. 16±19 As a result, NSAIDs are emerging as potentially powerful agents in the prevention of cancer, particularly those of epithelial origin. Recent publications suggest that AK is an early step in the development of SCC and should therefore be treated aggressively to stop the progression to SCC. 3, 4, 7, 20 However, not all AKs will progress to SCC, some, especially small lesions, will even spontaneously involute. At present there are no reliable methods to assess the progression rate of AK. Although it is important to diagnose and treat AK, not all patients will require destructive treatment on their ®rst visit; each case must be tailored to suit the needs of the patient. 5, 9 The availability of a new topical 3% diclofenac in 2.5% hyaluronan gel provides a new therapeutic option that is effective, well-tolerated, easy to administer and most importantly nondestructive. Consequently, it is more likely to be accepted by patients and allow early treatment of AKs without resorting to invasive methods. 
